Why Lymphoma Is One of the Most Re-Read Diagnoses

Why lymphoma is one of the most re-read diagnoses

Because getting the subtype right is both hard and consequential. Lymphoma is not one disease but a family of dozens of subtypes, and they are treated very differently — so an imprecise label changes the entire plan. Expert re-review reflects that difficulty: when lymphoma diagnoses were re-read by expert hematopathologists, major diagnostic revisions occurred in roughly one in six cases, and disagreement ranged from about 10% for Hodgkin lymphoma to as high as 75% for Burkitt lymphoma 1Ref 1Matasar MJ, Shi W, Silberstien J, et al. (2012).Expert second-opinion pathology review of lymphoma in the era of the World Health Organization classification.Expert lymphoma re-review (major revision in roughly one in six cases; disagreement from about 10% for Hodgkin to 75% for Burkitt) used to show frequent, subtype-dependent revision on expert lymphoma pathology review..

That is a much higher revision rate than pathology re-review produces across cancers generally, and it is the core reason a lymphoma second opinion is really a pathology second opinion. The value is not suspicion of your doctors; it is that this particular diagnosis rests on a demanding, interpretive read, and a hematopathologist who sees lymphoma daily is the person best placed to land the exact subtype.

How a lymphoma diagnosis is made — and why it is hard

A lymphoma diagnosis comes from a biopsy of a lymph node or affected tissue, read by a hematopathologist. The label is not final on appearance alone; it is assembled from several specialized tests, and the difficulty is that many subtypes look similar under the microscope until those tests separate them.

The pieces usually include:

• Morphology — how the tissue and cells appear under the microscope
• Immunohistochemistry and flow cytometry — the pattern of proteins and surface markers that defines the subtype
• Molecular and cytogenetic testing — gene rearrangements and chromosome changes that pin down specific types
• Enough tissue — an excisional or core biopsy that captures the node's architecture, which a small needle sample may miss

Because the modern classification recognizes so many entities, the exact subtype — indolent or aggressive, Hodgkin or non-Hodgkin, and the specific type within those — depends on reading all of this together correctly.

How often expert re-review changes the diagnosis

Across pathology generally, expert re-review overturns a diagnosis of major importance in a small fraction of cases — about 1.4% in a large referral-hospital series, still enough to alter treatment or prognosis 2Ref 2Kronz JD, Westra WH, Epstein JI (1999).Mandatory second opinion surgical pathology at a large referral hospital.Referral-hospital pathology re-review (1.4% with a changed diagnosis of major clinical importance) used as the baseline rate that lymphoma exceeds.. Lymphoma sits at the demanding end of that spectrum, where the fraction is far higher.

Part of the reason is that pathology of borderline categories is genuinely variable, even among skilled pathologists. When practicing pathologists interpreted breast biopsies, agreement with an expert reference reached only 48% for the borderline category of atypia, with cases both over- and under-called 3Ref 3Elmore JG, Longton GM, Carney PA, Geller BM, Onega T, Tosteson ANA, Nelson HD, Pepe MS, Allison KH, Schnitt SJ, O'Malley FP, Weaver DL (2015).Diagnostic Concordance Among Pathologists Interpreting Breast Biopsy Specimens.Breast-biopsy concordance study (only 48% agreement for the borderline category of atypia) used to illustrate that pathologist interpretation of borderline categories varies substantially, motivating expert re-review.. Lymphoma is full of such fine distinctions, where the gap between two subtypes is subtle but the treatments are not. That combination — subtle diagnosis, divergent treatment — is exactly what makes a second read worth it, and why a pathology slide re-read is the heart of a lymphoma second opinion.

Getting the subtype right before treatment starts

The reason timing matters is that the subtype decides the treatment, and treatments diverge sharply. An indolent lymphoma may be watched; an aggressive one is treated promptly; Hodgkin and the many non-Hodgkin types each follow their own regimens. Confirming the exact subtype before the plan is locked in is therefore high-value — and much of a second opinion's benefit is in refining that plan. In a review of newly diagnosed cancers, second opinions produced clinically meaningful changes in 35% of cases, most of them even when the original diagnosis was confirmed 4Ref 4Lipitz-Snyderman A, et al. (2023).Clinical value of second opinions in oncology: A retrospective review of changes in diagnosis and treatment recommendations.Oncology second-opinion review (clinically meaningful changes in 35% of cases, most even when the diagnosis was confirmed) used to show the value is largely in treatment refinement..

That is the practical case for moving early. A second read that confirms the subtype lets treatment proceed with confidence; one that revises it can redirect the whole course before the first cycle. The lymphoma second opinion is most useful before treatment begins, while the subtype can still steer the plan.

Staging and where a second opinion also looks

Beyond the diagnosis, a lymphoma second opinion checks the stage, which is largely built from imaging. Lymphoma is commonly staged with PET-CT, and imaging is interpreted rather than simply measured, so a subspecialist re-read can differ. When outside PET-CT scans were re-reviewed by subspecialists, at least one discordant opinion about malignancy appeared in 13% of cases 5Ref 5Ulaner GA, Mannelli L, Dunphy M (2017).Value of second-opinion review of outside institution PET-CT examinations.Subspecialist re-read of outside PET-CT exams (at least one discordant malignancy opinion in 13%) used to show imaging re-reads can change staging conclusions..

Stage shapes how much treatment is given and for how long, so an accurate read matters alongside the pathology. A second opinion at a center that manages lymphoma routinely often reviews the slides, the scans, and the clinical picture together, which is more informative than any single re-read on its own. In many centers this happens at a multidisciplinary conference, where a hematopathologist, an oncologist, and a radiologist look at the same case at once and reconcile the diagnosis with the stage. The aim is a diagnosis and a stage that more than one set of experts agree on before a long treatment plan begins.

How to get your slides reviewed

Start with the materials: the biopsy slides and paraffin blocks, the immunohistochemistry and flow cytometry reports, any molecular results, and your imaging. Seeking a second opinion is a normal part of cancer care, and you are entitled to copies of your records and pathology materials 6Ref 6American Cancer Society (2024).Seeking a Second Opinion.Patient-education guidance used for the point that seeking a cancer second opinion is normal and that patients are entitled to copies of their records and pathology materials.. For lymphoma, the slides and blocks are the essential thing to move, because the reviewer needs to look at the tissue directly.

A practical path:

• Gather the records for a second opinion in writing, and ask specifically for the pathology slides and blocks to be released.
• If only a small needle sample was taken and the diagnosis is uncertain, ask whether a larger biopsy is needed to classify the subtype.
• Choose a center that reads lymphoma frequently, and confirm how it wants the materials sent.

This is a common reason to seek a cancer second opinion early — while the diagnosis is being finalized and before a treatment plan is set. Because the physical slides are what travel, a lymphoma second opinion is usually a materials-based review at a specialty center rather than a purely remote video visit, and building in the extra day or two to ship them is almost always worth it.